-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In order to explore the clinical features and risk factors of epilepsy associated with glioma, Professor Liu Hongyi of Nanjing Brain Hospital conducted a retrospective study.
The results were published online in the September 2022 issue of the World Journal of Surgical Oncology
.
- Excerpted from the article chapter
【Ref: Ge H, et al.
World J Surg Oncol.
2022 Sep 19; 20(1):297.
doi: 10.
1186/s12957-022-02772-2.
】
Research background
The incidence of epilepsy in patients with glioblastoma (GBM) ranges from 30% to 60%.
Recent studies have reported that epilepsy promotes the growth
of gliomas.
In order to explore the clinical features and risk factors of epilepsy associated with glioma, Professor Liu Hongyi of Nanjing Brain Hospital conducted a retrospective study.
The results were published online in the September 2022 issue of the World Journal of Surgical Oncology
.
Research methods
The authors included the clinical data of 485 glioma patients in Nanjing Brain Hospital and conducted four regular follow-ups to analyze the clinical characteristics of glioma patients with seizures and their relationship
with survival.
The results showed that patients with supratentorial glioma had a higher incidence of epilepsy, and recurrent or multiple gliomas did not affect the incidence of epilepsy, which was independent
of gender.
Young patients with WHO grade II glioma are most likely to develop epilepsy, while patients with grade IV glioma are least likely to have seizures
.
The results of multivariate prognosis analysis showed that epilepsy had a significant impact on the survival rate of patients with grade II and III glioma.
Independently correlated
with survival in patients with grade IV glioma.
In all tumor grades, the 1-year survival rate was higher in the epilepsy group than in the non-epilepsy group
.
There was no difference
in Karnovsky's performance status score between patients with glioma with epilepsy and those without epilepsy.
Study results
The study found that younger patients with glioma and WHO grade II glioma patients were most likely to have seizures, while older adults and patients with grade IV glioma were the least
likely to have seizures.
Epilepsy does not cause symptoms to worsen
in patients with gliomas.
GBM has the lowest survival rate compared to other types of glioma, but epilepsy improves survival in GBM
.
